Prostacyclin therapy is a mainstay of the management of pulmonary arterial hypertension (PAH).

Pulmonary arterial hypertension (PAH, or PH Group 1), a disease of aberrant pulmonary vascular remodeling, causing progressive right heart failure (RHF) due to elevation of pulmonary vascular resistance (PVR).

In this Community Call, we discussed: 

• Implications of mean pulmonary arterial wedge pressure trajectories in PAH
• Myeloid cell derived IL1β contributes to PH in HFpEF
• Transcriptional profiling unveils molecular subgroups of adaptive and maladaptive right ventricular remodeling in pulmonary hypertension

'Bacteria' is part of the Microbes Virtual Symposium series by the iPVD, a global education programme that highlights top-notch research on inflammation and infectious PVD.

Pulmonary hypertension in sickle cell disease (SCD) is a complex phenomenon resulting from multiple overlapping etiologies, including pulmonary vasoconstriction in the setting of chronic hemolytic...

Dr. John Newman passed from this mortal life on February 20, 2024. I celebrate John's life, even as I mourn his passing...

John H. Newman, MD passed away peacefully after a brief illness on February 20, 2024. He was the true triple threat: investigator, educator, and clinician...

Pulmonary hypertension (PH) is a progressive and invalidating condition despite available therapy. Addressing complications such as left main coronary artery compression...

Several indices of right heart remodeling and function have been associated with survival in pulmonary arterial hypertension (PAH). Outcome analysis and physiological relationships...

This collection comprises of the 189 accepted abstracts from the PVRI 2024 Annual Congress which took place in London in January 2024.